Silvia Riondino, MD, received her PhD in Experimental Medicine, and a Post-PhD at the University of Rome “La Sapienza”. She is currently a Researcher in Oncology at the University of Tor Vergata, Department of Systems Medicine, Medical Oncology Unit. Her main fields of interest have been the study of 1) biochemical pathways of platelet pathology and physiology; 2) pathophysiological mechanisms responsible for the thrombophilia state associated with chronic degenerative diseases (chronic obstructive pulmonary disease, cardiovascular diseases), with cardiovascular risk factors (diabetes, hypercholesterolemia, hyperhomocysteinemia, obesity) and with neoplastic conditions such as breast, colorectal and lung cancer; 3) mechanisms involved in the pathogenesis of several chronic disabling diseases, with particular attention to the interactions between inflammation, angiogenesis and hemostasis, to identify biomarkers, “emerging” risk factors and possible determinants of outcomes in patients with chronic diseases, both in primary prevention and during the therapeutic/rehabilitation phases; 4) “quality criteria” to be applied to biological samples for the Biological Bank BioBIM (IRCCS San Raffaele) and PTV-Bio.Ca.Re (UniversityHospital “Tor Vergata”) projects; 5) determinants of oncological diseases in terms of associated risk conditions, antineoplastic treatment efficacy and adverse events, and existing sex and gender differences.